Remedium Bio Partners With Eli Lilly on Gene Therapy Bet for Diabetes and Obesity
Remedium Bio, a Boston-based gene therapy startup, announced a strategic collaboration with Eli Lilly on September 8, 2024, aimed at developing single-dose treatments for type 2 diabetes and obesity. Under the deal, Lilly will make an upfront payment and equity investment, with additional milestone payments and tiered royalties tied to future sales, though neither party disclosed specific financial terms.
The partnership centers on Remedium's Prometheus platform, which the company describes as an adjustable-dose gene therapy system capable of replacing daily or weekly protein injections with a one-time, tunable treatment. Unlike traditional gene therapies that deliver a fixed genetic payload, Prometheus allows clinicians to dial expression levels up or down after the initial dose—a technical feat that could address one of gene therapy's longstanding limitations.
The platform works by targeting adipocytes (fat cells) through subcutaneous delivery, keeping the genetic material localized while allowing the secreted therapeutic protein to circulate throughout the body. According to a peer-reviewed study published in Gene on April 23, 2024, the system achieves zero-order release kinetics, meaning it delivers a steady state of medication rather than the peaks and troughs associated with repeated injections. It can accommodate a range of payloads, from small peptides to full-length antibodies.
GLP-1 Gene Therapy Takes Center Stage
Remedium's most advanced metabolic program, RMD1202, takes aim at the booming GLP-1 market. The candidate is a gene therapy version of the GLP-1 receptor agonist, the same mechanism behind blockbuster drugs like Wegovy and Ozempic. At the American Diabetes Association's 2024 Scientific Sessions in June, the company presented preclinical data showing that a single injection of RMD1202 outperformed daily GLP-1 protein injections in diet-induced obesity mouse models.
"The progress made by the team on the development of RMD1202 gives hope of a future where durable, single injection treatment options are available to patients with potentially improved tolerability, due to the zero-order therapeutic kinetics," the company said in a June 13, 2024 statement.
For Lilly, the deal represents a hedge on next-generation delivery technology at a time when the pharmaceutical giant already dominates the incretin space with its own injectable and oral therapies. The collaboration will span multiple targets across type 2 diabetes and obesity, though specific programs beyond RMD1202 have not been detailed.
"We are thrilled to collaborate with Lilly, a global leader in metabolic disease therapeutics, to bring durable, tunable therapies to patients living with Type 2 diabetes and obesity," Remedium said in its September 8 announcement.
A Gateway to Validation
The Lilly partnership emerged four months after Remedium joined Lilly Gateway Labs in Boston, part of the company's Catalyze360 initiative designed to support emerging biotech firms. That May 12, 2025 residency announcement hinted at broader ambitions. "Joining with Lilly Gateway Labs will accelerate development of our groundbreaking technology to indications beyond our GLP-1 lead candidate," Remedium said at the time.
Founded in 2020 and now headquartered at 15 Necco Street in Boston, Remedium has quietly built a pipeline that extends beyond metabolism. RMD1501 targets neuroprotection and neuroregeneration in ischemic stroke, with preclinical results published in Restorative Neurology and Neuroscience in August 2024. A separate osteoarthritis program using AAV2-FGF18 showed what the company characterized as disease-modifying effects in a study that appeared in Current Gene Therapy on January 30, 2024, according to Remedium Bio.
The company's financial backing remains modest by biotech standards. Before Lilly's equity investment, Remedium had raised over $2.3 million in an expanded seed round in August 2022, according to a company press release. CBInsights lists an additional $1.5 million venture round dated May 18, 2026, with a corresponding Form D filing, though details about the investors in that round were not disclosed.
Backers include LifeSpan Vision Ventures, Healthspan Capital (which invested in September 2024), and Longevitytech.fund. The company also secured a National Science Foundation SBIR Phase I grant in August 2023 to further develop the Prometheus platform.
Team and Trajectory
Frank Luppino, Remedium's president and CEO, previously served as chief operating officer at Anika Therapeutics. Chief Technology Officer Alex Goraltchouk brings experience from stints at Allergan, Regeneron, and Biogen before co-founding the startup.
LifeSpan Vision Ventures framed the Lilly deal as validation of the platform's commercial potential. The collaboration represents "a powerful validation of their platform and is an important step toward developing interventions that extend healthspan," the investor said in a September 23, 2025 press release.
Goodwin Procter advised Remedium on the transaction, according to a statement from the law firm in September 2025.
Whether Prometheus can deliver on its promise to transform chronic disease management with a single shot remains an open question. Gene therapy has stumbled before on safety concerns and durability issues. But for now, Remedium has secured a partner with deep pockets and a vested interest in keeping its metabolic disease franchise ahead of the curve.
